WFG Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

WFG Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$6K	Hold	100	–	–	﹤0.01%	1253
2017 Q1	$6K	Hold	100	–	–	﹤0.01%	1188
2016 Q4	$5K	Buy	+100	New	+$5.34K	﹤0.01%	1275
2014 Q2	–	Sell	-100	Closed	-$5.94K	–	2045
2014 Q1	$6K	Hold	100	–	–	﹤0.01%	1593
2013 Q4	$5K	Buy	+100	New	+$5.06K	﹤0.01%	1758

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

SCM

Stuyvesant Capital Management Armonk, New York $41.1M AUM 17.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

WFG Advisors's PPH Position: Q2 2017 in Review

WFG Advisors held its VanEck Pharmaceutical ETF (PPH) position steady in Q2 2017 at 100 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1253.

WFG Advisors first reported a position in PPH in Q4 2013 and has held it in 5 quarters since. 50 funds tracked by Wall St. Rank hold PPH as of Q2 2017.

WFG Advisors held 100 shares of VanEck Pharmaceutical ETF worth $6K as of Q2 2017.
WFG Advisors left its VanEck Pharmaceutical ETF share count unchanged in Q2 2017.
VanEck Pharmaceutical ETF made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1253 holding.
WFG Advisors first reported a position in VanEck Pharmaceutical ETF in Q4 2013 and has held it in 5 quarters since.
50 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.